The primary financial and corporate purpose of Vaxart issuing and maintaining publicly traded stock on the Nasdaq exchange is to raise vital capital to fund ongoing research, development, and clinical trials for its innovative oral vaccine platform. Unlike established manufacturing corporations that distribute stable dividend yields from mature commercial sales, clinical-stage biopharmaceutical companies rely heavily on equity offerings, warrants, and public stock markets to finance expensive laboratory research, manufacturing scaling, and human clinical trials required to bring novel pill-based vaccines through regulatory approval stages.